Recombinant monoclonal antibody to CTGF. Pamrevlumab is a human monoclonal antibody that can be potentially used in the treatment of Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer. It inhibits connective tissue growth factor (CTGF).
Figure 1 Pharmacokinetic and pharmacodynamic profile of gemcitabine in KPC mice; error bars represent standard error of the mean (SEM).
(A) Pharmacokinetic profile of native (2′,2′-difluorodeoxycytidine; dFdC) and inactivated (2′,2′-difluorodeoxyuridine; dFdU) gemcitabine metabolites in plasma of KPC mice (n = 38 in total) following a single i.p. injection of 100 mg/kg dFdC. The following time points were analyzed: 0 h (n = 5), 1 h (n = 7), 2 h (n = 7), 4 h (n = 7), 6 h (n = 7), and 10 h (n = 5). (B) Pharmacokinetic profile of native (dFdC), inactivated (dFdU), and active (2′,2′-difluorodeoxycytidine-5′-triphosphate; dFdCTP) gemcitabine metabolites in tumor biopsies of KPC mice (n = 65 in total) corresponding to the same samples displayed in A for 0 h (n = 4), 1 h (n = 21), 2 h (n = 15), 4 h (n = 19), 6 h (n = 7), and 10 h (n = 5). (C) Pharmacodynamic profile of cleaved caspase 3 and phosphohistone H3 immunohistochemistry in tumor samples from KPC mice (n = 65 in total) following a single i.p. injection of 100 mg/kg dFdC. (D) Quantification of proliferation (PH3) and apoptosis (CC3) in small intestinal cells following a single dose of 100 mg/kg i.p. of gemcitabine. Each time point represents ≥5 mice. (E) Preenrollment tumor volumes of the 9-d shortterm study (n ≥ 6 each cohort) showing no significant differences before enrollment. (F) Schematic of the short-term 9-d trial for the combination therapy of FG-3019 and gemcitabine in tumor-bearing KPC mice.
Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.
Figure 2 CTGF is present in KPC tumors and plasma.
Representative CTGF immunohistochemistry in normal pancreas (NP) tissue (n = 3; Top Left), pancreatic intraepithelial neoplasia (PanIN) (n = 6; Top Right), and a murine pancreatic cancer specimen (n = 11) with stromal (Middle) and tumor cell (Bottom) expression patterns.
Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.
Figure 3 CTGF is present in KPC tumors and plasma.
Western blot analysis of CTGF, α-SMA, and E-cadherin in primary murine tumor and cancer-associated fibroblast cell lines.
Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.
Figure 4 CTGF is present in KPC tumors and plasma.
Plasma of WT (n = 7) and tumor-bearing KPC mice (n = 30; P < 0.0001; LLOQ, 9.4 ng/mL) by ELISA.
Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.
Figure 5 FG-3019 induces neoplastic apoptosis but does not alter tumor stroma, vasculature, and gemcitabine pharmacology over a 9-d course.
Representative coimmunofluorescence images of DAPI (blue), E-cadherin (green), and CC3 (orange) in each of the 9 d-treated cohorts.
Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-CTGF ADCC Recombinant Antibody (Pamrevlumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTGF. Pamrevlumab is a human monoclonal antibody that can be potentially used in the treatment of Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer. It inhibits connective tissue growth factor (CTGF).
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1576z | Mouse Anti-CTGF Recombinant Antibody (clone 32G9) | ELISA, IHC | Mouse IgG1 |
HPAB-0181-YC | Human Anti-CTGF Recombinant Antibody (HPAB-0181-YC) | ELISA, FuncS | Human IgG |
MRO-1793-CN | Rabbit Anti-CTGF Polyclonal Antibody (MRO-1793-CN) | WB, IF, IHC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-080MZ | Mouse Anti-CTGF Recombinant Antibody (TAB-080MZ) | ELISA | Mouse IgG |
TAB-080MZ-S(P) | Mouse Anti-CTGF Recombinant Antibody; scFv Fragment (TAB-080MZ-S(P)) | ELISA | Mouse scFv |
TAB-080MZ-F(E) | Mouse Anti-CTGF Recombinant Antibody; Fab Fragment (TAB-080MZ-F(E)) | ELISA | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-081MZ | Human Anti-CTGF Recombinant Antibody (TAB-081MZ) | ELISA | Human IgG |
TAB-082MZ | Human Anti-CTGF Recombinant Antibody (TAB-082MZ) | ELISA | Human IgG |
TAB-081MZ-S(P) | Human Anti-CTGF Recombinant Antibody; scFv Fragment (TAB-081MZ-S(P)) | ELISA | Human scFv |
TAB-082MZ-S(P) | Human Anti-CTGF Recombinant Antibody; scFv Fragment (TAB-082MZ-S(P)) | ELISA | Human scFv |
TAB-081MZ-F(E) | Human Anti-CTGF Recombinant Antibody; Fab Fragment (TAB-081MZ-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-119LC | Recombinant Anti-Human CTGF Antibody (Fc glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0181-YC-S(P) | Human Anti-CTGF Recombinant Antibody; scFv Fragment (HPAB-0181-YC-S(P)) | ELISA, FuncS | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0181-YC-F(E) | Human Anti-CTGF Recombinant Antibody; Fab Fragment (HPAB-0181-YC-F(E)) | ELISA, FuncS | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-443CQ | Afuco™ Anti-CTGF ADCC Recombinant Antibody (Pamrevlumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-443CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.